Factors associated with spontaneous reporting of adverse drug reactions in Japan

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 5, 2013, Pages 468-476

  Yamada, Toru ^a   Watanabe, Yuka ^a   Kusama, Makiko ^a   Sugiyama, Yuichi ^a   Ono, Shunsuke ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Adverse drug reaction; Early post marketing phase vigilance; Launch lag; Pharmacoepidemiology; Spontaneous reporting

Indexed keywords

AGENTS AFFECTING METABOLISM; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BIOLOGICAL PRODUCT; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; NEW DRUG;

ARTICLE; DATA BASE; DRUG APPROVAL; DRUG CONTROL; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EARLY POST MARKETING PHASE VIGILANCE; HUMAN; JAPAN; PRIORITY JOURNAL; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG AND NARCOTIC CONTROL; DRUG APPROVAL; DRUG INDUSTRY; HUMANS; JAPAN; MODELS, STATISTICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOVIGILANCE;

EID: 84877607711     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3378     Document Type: Article

References (23)

1. Wilson MA, Thabane L, Holbrook A. Application of data mining techniques in pharmacovigilance. Br J Clin Pharmacol 2003; 57: 127-134.
2. Olson M. The risk we bear: the effects of review speed and industry user fees on new drug safety. J Health Econ 2008; 27: 175-200.
3. Olson M. Are novel drugs more risky for patients than less novel drugs? J Health Econ 2004; 23: 1135-1158.
4. Motola D, Vargiu A, Leone R, et al. Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy. Drug Saf 2008; 31: 609-616.
5. Aagaard L, Stenver DI, Hansen EH. Structure and process in spontaneous ADR reporting systems: a comparative study of Australia and Denmark. Pharm World Sci 2008; 30: 563-570.
6. Zolezzi M, Parsotam N. Adverse drug reaction reporting in New Zealand: implications for pharmacists. Ther Clin Risk Manag 2005; 2: 181-188.
7. McLernon D, Bond C, Hannaford P, Watson M, et al. Adverse drug reaction reporting in the UK: A Retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals. Drug Saf 2010; 33: 775-788.
8. Hazell L, Shakir SAW. Under-reporting of adverse drug reactions. A systematic review. Drug Saf 2006; 29: 385-396.
9. Hirai Y, Kinoshita H, Kusama M, Yasuda K, Sugiyama Y, Ono S. Delays in new drug applications in Japan and industrial R&D strategies. Clin Pharmacol Ther 2010; 87: 212-218.
10. Tsuji K, Tsutani K. Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situations. Eur J Pharm Biopharm 2008; 68: 496-502.
11. Huang S-M, Temple R. Is this the drug or dose for you?: Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin Pharmacol Ther 2008; 82: 287-294.
12. FDA. Guidance for industry. Collection of race and ethnicity data in clinical trials. FDA CDER/CBER/CDRH/OC, Rockville; September 2005. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm126396.pdf [4 October 2012].
13. FDA. Drug safety communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. FDA, Silver Spring; Jun 2011.http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm [4 October 2012].
14. EMA. Update on ongoing European review of pioglitazone-containing medicines. EMA, London; Jun 2011. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/06/news_detail_001275.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1&jsenabled=true [4 October 2012].
15. PMDA. Search site for reported serious ADRs (in Japanese). PMDA, Tokyo; http://www.info.pmda.go.jp/fukusayou/menu_fukusayou_attention.html [4 October 2012].
16. Lasser K, Allen P, Woolhandler S, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287: 2215-2220.
17. FDA. The clinical impact of adverse event reporting; A MedWatch continuing education article. FDA/CDER, Rockville; 1996. http://www.fda.gov/downloads/Safety/MedWatch/UCM168505.pdf [4 October 2012].
18. Yamada T, Kusama M, Hirai Y, Arnold FL, Sugiyama Y, Ono S. Analysis of pharmaceutical safety-related regulatory actions in Japan: Do tradeoffs exist between safer drugs and launch delay? Ann Pharmacother 2010; 44: 1976-1985.
19. MHLW. Q & A on use-results surveys conducted as All-Case Surveillance and Early Post-Marketing Phase Vigilance (EPPV) for prescription drugs. MHLW/PFSB/Safety Division, Tokyo; September 2009. http://www.pmda.go.jp/english/service/pdf/notifications/20090907.pdf [4 October 2012].
20. FDA. Guidance medication guides - distribution requirements and inclusion in risk evaluation and mitigation strategies (REMS). FDA/CDER/CBER, Silver Spring; November 2011. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM244570.pdf [4 October 2012].
21. Chintagunta P, Desiraju R. Strategic detailing and pricing behaviour in international markets. Marketing Sci 2005; 24: 67-80.
22. Canli H, Saatci E, Bozdemir N, Akpinar E, Kiroglu M. The antibiotic prescribing behavior of physicians for acute tonsillopharyngitis in primary care. Ethiop Med J 2006; 44: 139-143.
23. Steinman MA, Harper GM, Chren MM, et al. Characteristics and impact of drug detailing for gabapentin. PLoS Med 2007; 4: e134. doi:10.1371/journal.pmed.0040134